| The treatment of advanced melanoma: therapeutic update A Villani, L Potestio, G Fabbrocini, G Troncone, U Malapelle, M Scalvenzi International journal of molecular sciences 23 (12), 6388, 2022 | 90 | 2022 |
| Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study M Megna, N Tommasino, L Potestio, T Battista, A Ruggiero, M Noto, ... Journal of Dermatological Treatment 33 (6), 2813-2820, 2022 | 64 | 2022 |
| New emerging treatment options for advanced basal cell carcinoma and squamous cell carcinoma A Villani, L Potestio, G Fabbrocini, M Scalvenzi Advances in therapy 39 (3), 1164-1178, 2022 | 60 | 2022 |
| New frontiers in personalized medicine in psoriasis E Camela, L Potestio, G Fabbrocini, A Ruggiero, M Megna Expert Opinion on Biological Therapy 22 (12), 1431-1433, 2022 | 56 | 2022 |
| Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience F Martora, M Megna, T Battista, L Potestio, MC Annunziata, C Marasca, ... Clinical, Cosmetic and Investigational Dermatology, 135-148, 2023 | 54 | 2023 |
| Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study M Megna, L Potestio, A Ruggiero, E Camela, G Fabbrocini Journal of Dermatological Treatment 33 (5), 2560-2564, 2022 | 53 | 2022 |
| Teledermatology and inflammatory skin conditions during COVID-19 era: new perspectives and applications C Marasca, MC Annunziata, E Camela, A Di Guida, L Fornaro, M Megna, ... Journal of clinical medicine 11 (6), 1511, 2022 | 53 | 2022 |
| Clinical phenotypes of adult atopic dermatitis and related therapies C Patruno, L Potestio, M Napolitano Current Opinion in Allergy and Clinical Immunology 22 (4), 242-249, 2022 | 52 | 2022 |
| Reply to “Psoriasis exacerbation after COVID‐19 vaccination: report of 14 cases from a single centre” by Sotiriou E et al M Megna, L Potestio, L Gallo, G Caiazzo, A Ruggiero, G Fabbrocini Journal of the European Academy of Dermatology and Venereology 36 (1), e11, 2021 | 49 | 2021 |
| Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients M Megna, E Camela, T Battista, L Genco, F Martora, M Noto, V Picone, ... Expert Opinion on Drug Safety 22 (1), 43-58, 2023 | 47 | 2023 |
| Dupilumab treatment in children aged 6–11 years with atopic dermatitis: a multicentre, real-life study M Napolitano, G Fabbrocini, I Neri, L Stingeni, V Boccaletti, V Piccolo, ... Pediatric Drugs 24 (6), 671-678, 2022 | 47 | 2022 |
| Scabies outbreak during COVID‐19: an Italian experience. M De Lucia, L Potestio, L Costanzo, G Fabbrocini, L Gallo International journal of dermatology 60 (10), 2021 | 46 | 2021 |
| Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real‐life experience. M Napolitano, G Fabbrocini, L Genco, F Martora, L Potestio, C Patruno Journal of the European Academy of Dermatology & Venereology 36 (9), 2022 | 45 | 2022 |
| Risankizumab treatment in psoriasis patients who failed anti‐IL17: a 52‐week real‐life study M Megna, L Potestio, A Ruggiero, E Camela, G Fabbrocini Dermatologic Therapy 35 (7), e15524, 2022 | 45 | 2022 |
| The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs E Camela, L Potestio, G Fabbrocini, S Pallotta, M Megna Expert opinion on investigational drugs 32 (6), 537-552, 2023 | 44 | 2023 |
| Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients M Megna, E Camela, T Battista, L Genco, F Martora, M Noto, V Picone, ... Expert Opinion on Drug Safety 22 (1), 25-41, 2023 | 44 | 2023 |
| Treating psoriasis in the elderly: biologics and small molecules M Megna, L Potestio, G Fabbrocini, E Camela Expert Opinion on Biological Therapy 22 (12), 1503-1520, 2022 | 41 | 2022 |
| Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting M Megna, L Potestio, E Camela, G Fabbrocini, A Ruggiero Dermatologic Therapy 35 (9), e15667, 2022 | 41 | 2022 |
| Bimekizumab for the treatment of psoriasis: a review of the current knowledge A Ruggiero, L Potestio, E Camela, G Fabbrocini, M Megna Psoriasis: Targets and Therapy, 127-137, 2022 | 40 | 2022 |
| Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis) L Gargiulo, A Narcisi, L Ibba, A Balato, L Bianchi, P Brianti, D Buononato, ... Frontiers in Medicine 10, 1243843, 2023 | 39 | 2023 |
